The future of Exact Sciences Corp. (EXAS) Stock is still in tatters?

The Benchmark Company raised the price target for the Exact Sciences Corp. (NASDAQ:EXAS) stock from “a Hold” to “a Buy”. The rating was released on January 02, 2024, according to finviz. The research report from Wolfe Research has initiated the stock to Outperform, with a price target set at $95. The stock was upgraded by Piper Sandler, who disclosed in a research note on October 10, 2023, from Neutral to Overweight and set the price objective to $90. In their research brief published September 28, 2023, Bernstein analysts initiated the Exact Sciences Corp. stock to Outperform with a price target of $83.

Historical Earnings Surprises and Revenue Forecasts

Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of -$0.27 during the last quarter as opposed to a consensus estimate of -$0.46, which indicates the company beat its estimate by $0.19, which implies that the company surprised the market by 41.30%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2024) is -$0.46. This is an average of 15 analysts’ earnings, where the high earnings per share estimate is -$0.17 and the low earnings per share estimate is -$0.63. According to 20 analyst estimates, an average revenue estimate of $628.92M is projected for the current quarter with a high revenue estimate of $682M and a low estimate of $619.99M.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated 11.39% within the last five trades and 22.64% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 2.37% in the last 6 months and -8.75% was subtracted to its value over the previous 3 months. EXAS stock is trading at a margin of 13.72%, 11.77% and -5.21% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

As of the close of trading, EXAS deals in the Healthcare domain. The stock is trading -31.47 percent below its 52-week high and 23.21 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is -0.6. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Exact Sciences Corp.’s Profitability and Valuation Ratios Tell Us About the Stock?

With regard to the profitability of the company, the operating margin is currently at -12.20 percent and the profit margin is -8.17 percent, and the company has reported a gross margin of 70.14 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.

The stock’s market cap achieved a total value of $12.54 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 556.22. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 5.02 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 3.98, which equates the market value of a stock with its book value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.04 percent of Exact Sciences Corp. shares are owned by insiders, and 90.12 percent are held by financial institutions. Conroy Kevin T, the President and CEO at Exact Sciences Corp. (EXAS) has sold 8,271 shares of firm on Mar 01 ’24 at a price of $59.32 against the total amount of $0.49 million. In another inside trade, LEVANGIE DANIEL J, Director of Exact Sciences Corp. (NASDAQ:EXAS) sold 5,000 shares of the firm on Mar 01 ’24 for a total worth of $0.29 million at a price of $57.50. An inside trade which took place on Mar 01 ’24, Chief Commercial Officer of Exact Sciences Corp. Cunningham Everett sold 2,412 shares of firm against total price of $0.14 million at the cost of $59.32 per share.

Most Popular

Related Posts